Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Schrödinger Closes $85 Million Round led by Gates Foundation and WuXi AppTec

publication date: Jan 7, 2019

Schrödinger of New York City closed an $85 million financing to support its drug discovery platform, which is based on advanced molecular simulations. The funding was led by the Bill and Melinda Gates Foundation Trust and WuXi AppTec’s Corporate Venture Fund. In October 2018, WuXi AppTec formed Faxian Therapeutics with Schrödinger. Faxian will combine WuXi's lead optimization CRO with molecules discovered by Schrödinger's precision molecular design platforms. Faxian was formed to discover novel insights into the chemistry and biology of a target and indication. More details....

Stock Symbol: (SHA: 603259; HK: 2359)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.